XML 34 R22.htm IDEA: XBRL DOCUMENT v3.25.3
Segment and Related Information
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Segment and Related Information Segment and Related Information
The Company derives revenues through the delivery of test reports for our molecular diagnostic tests. All of our operations are located within the United States and our business is focused on the U.S. market.
We have a single reportable segment consisting of a single operating segment.
The measures of segment (loss) income for of our single reportable segment were as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
Net revenues from external customers(1)
$83,043 $85,782 $257,219 $245,758 
Significant segment expenses:
Personnel costs52,863 48,732 156,614 142,699 
Organizational and marketing costs11,267 10,271 39,983 33,106 
Inventory usage6,127 5,191 16,316 14,991 
Clinical studies and publication costs2,183 2,188 6,191 8,002 
Professional services2,524 2,559 8,398 8,103 
Other segment items8,580 14,572 51,543 30,202 
Segment (loss) income$(501)$2,269 $(21,826)$8,655 
(1)For information on disaggregation of segment revenue by type and information about payor concentration, see Note 3.
Other Segment Items
Other segment items include all other operating expenses types to included IT service and software licensing costs, fixed and variable expenses incurred for leasing of facilities and equipment, depreciation and amortization, gain or losses on disposal of fixed assets in the routine course of business, fair value adjustment for equity securities, realized gains or losses on investment securities, administrative costs, expense for use of prepaids to include insurance premiums and warranties for lab equipment, public company costs (less audit fees), interest and other non-operating income, and income tax expense or benefits. Our CODM does not individually review budgets or results for these activities.
Other amounts included in the measure of segment (loss) income were as follows (in thousands):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
Interest income$2,833 $3,404 $8,876 $9,544 
Interest expense(24)(201)(62)(485)
Depreciation and amortization3,816 3,541 36,994 10,229 
Income tax expense (benefit)115 6,013 (4,974)5,024 
Stock-based compensation expense12,100 13,027 34,487 38,881 
Changes in fair value of equity securities3,561 — 3,321 — 
Total assets for our reportable segment were located in the United States and were $562.8 million and $531.2 million as of September 30, 2025 and December 31, 2024, respectively. Expenditures for additions to long-lived assets were $12.5 million and $5.8 million for the three months ended September 30, 2025 and 2024, respectively, $31.1 million and $21.1 million for the nine months ended September 30, 2025, and 2024, respectively.